Telix Pharmaceuticals Ltd ADR SEC Filings

TLX NASDAQ

Welcome to our dedicated page for Telix Pharmaceuticals ADR SEC filings (Ticker: TLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Telix Pharmaceuticals’ breakthrough radiopharmaceutical pipeline means every FDA decision, clinical-trial update, or isotope supply agreement can swing valuation overnight. Yet investors trying to decode a 300-page annual report or match Form 4 buys against drug milestones often ask, “Where can I find Telix Pharmaceuticals quarterly earnings report 10-Q filing?” or “How do I track Telix Pharmaceuticals insider trading Form 4 transactions?” Stock Titan’s AI-powered SEC dashboard answers those needs in seconds.

Our platform pulls every disclosure—10-K, 10-Q, 8-K, DEF 14A, and more—directly from EDGAR the moment Telix files. Then AI summarizes the parts that matter: pipeline progress in the “Telix Pharmaceuticals annual report 10-K simplified,” revenue from the Illuccix imaging agent inside each “Telix Pharmaceuticals earnings report filing analysis,” and radioactive isotope supply risks buried deep in a “Telix Pharmaceuticals 8-K material events explained.” Interactive highlights point you to segment revenue, R&D spend, and clinical timelines, while real-time alerts surface “Telix Pharmaceuticals Form 4 insider transactions real-time” so you can spot executive conviction ahead of catalysts.

No more sifting through dense footnotes. With succinct AI commentary, you’ll move from “understanding Telix Pharmaceuticals SEC documents with AI” to acting on them. Use our filters to compare periods, export key tables, or set triggers for “Telix Pharmaceuticals executive stock transactions Form 4.” Whether you’re evaluating dilution risk in the proxy or forecasting sales from new radioligand therapies, Stock Titan equips you with clear, timely intelligence—saving hours and sharpening decisions.

AI-powered summaries and red-flag alerts
Complete, real-time coverage of all Telix filings
Instant access to insider trades and executive compensation
Side-by-side comparison of quarterly and annual reports

07/09/2025 07:44 AM

Filing

[6-K] Telix Pharmaceuticals Limited American Current Report (Foreign Issuer)

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-4.85%

FAQ

What is the current stock price of Telix Pharmaceuticals ADR (TLX)?

The current stock price of Telix Pharmaceuticals ADR (TLX) is $15.53 as of July 16, 2025.

What is the market cap of Telix Pharmaceuticals ADR (TLX)?

The market cap of Telix Pharmaceuticals ADR (TLX) is approximately 5.3B.

What is the primary focus of Telix Pharmaceuticals?

Telix develops and commercializes radiopharmaceuticals designed for both diagnostic imaging and targeted radioligand therapy to manage cancer.

How do Telix's products work in cancer detection and treatment?

At low doses, the products bind to cancer cells for imaging via PET scans, while at higher doses, they deliver targeted radiation to treat tumors.

What therapeutic areas does Telix target?

The company primarily focuses on oncology, with a significant emphasis on prostate cancer imaging and treatment, among other cancers.

How does Telix generate revenue?

Revenue is primarily derived from the commercialization of its approved imaging agents in key markets, notably in the United States, alongside a robust development pipeline.

What differentiates Telix from its competitors?

Telix distinguishes itself through its precise targeting technology, which integrates advanced imaging with therapeutic radiology, ensuring greater accuracy in cancer management.

What role does research and development play at Telix?

R&D is integral to Telix’s operations, driving innovation and the advancement of a broad pipeline of radiopharmaceutical therapies through rigorous clinical and preclinical investigations.

Which markets does Telix serve?

Telix operates globally, with significant market presence in regions including the United States, Australia, Europe, Canada, and Japan, ensuring broad access to its technology.